Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

NCT07584954 | Recruiting Phase 1 DMC

• 2 other identifiers: IUAb220910-01CTR20241263
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 6

Brief Summary

This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor

Conditions

Solid Tumor Cancer; Solid Tumor Cancer Treatment With Immunotherapy

Keywords

cytotoxic antibody; PD-L1

Outcome Measures

Primary Outcomes (1)

• ORR

  Objective response rate (ORR), defined as the number of subjects with complete response (CR) or partial response (PR) divided by the number of subjects in the population of interest.

  2 years

Secondary Outcomes (4)

• DOR

  2 years

• PFS

  2 years

• OS

  2 years

• Incidence and severity of adverse events (AEs)

  2 years

Study Arms (1)

IUAb190708 treatment

EXPERIMENTAL

After a screening phase of 28 days, eligible subjects will be enrolled into IUAb190708 group. * Dose escalation: 0.2, 1, 3, 10, 15 mg/kg * Dose expansion: 10 mg/kg or 15 mg/kg * IUAb190708 is administered intravenously, q2w

Drug: IUAb190708, a cytotoxic antibody

Interventions

IUAb190708, a cytotoxic antibody DRUG

a novel cytotoxic anti-PD-L1 antibody

IUAb190708 treatment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female adult, age 18 - 75, understanding and voluntarily signing an informed consent form
• A histologically confirmed diagnosis of Metastatic or locally advanced solid tumors, ineffective management of therapeutic regimen or currently no approved treatment available for the tumor, or unsuitable or refusing to receive standard treatment
• In Phase Ia, for tumors with approved indications of anti PD-1/PD-L1 treatment, unrestricted to PD-L1 expression; for tumors that have not yet been approved for indications, positive expression of PD-L1 required. In Phase Ib, positive expression of PD-L1 is required
• Subjects should provide fresh or archived tissue samples
• Subjects must have at least one measurable lesion per iRECIST
• Life expectancy ≥ 3 months
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
• Adequate organ function, and no blood transfusion, erythropoietin (EPO), and granulocyte colony-stimulating factor at least 14 days before the study drug administration
• All the female of child-bearing age must have a negative pregnancy test (unine or serum) during screening period and agree to use effective medical contraception from written informed consent to at least 6 months after the last administration of the study drug. Male partners also must agree to use effective medical contraception from written informed consent to at least 6 months after the last administration of the study drug.

You may not qualify if:

• Serious/active infection or infection requiring intravenous antibiotic treatment within 4 weeks prior to the first dose of the study drug
• Receiving nitrosourea and mitomycin C within 6 weeks prior to the first dose of the study drug; receiving oral fluorouracil derivatives or small molecule targeted drugs within 2 weeks prior to the first dose or 5 half-lives of the drug (whichever is longer); receiving endocrine therapy, Immunotherapy, or Traditional Chinese Medicine for anti-tumor indications within 2 weeks prior to the first dose of the study drug; receiving other anti-tumor therapies, such as chemotherapy, radiation, biotherapy, besides as described above treatments, within 4 weeks prior to the first dose of the study drug
• Having other primary active malignant tumors within 5 years prior to the first dose of the study drug
• Having clinically significant cardiovascular diseases,
• Primary tumors of central nervous system or CNS metastatic tumors that have failed local treatment. For asymptomatic or clinically stable symptoms without the need for steroid hormones and other treatments for CNS metastasis lasting ≥ 28 days, CNS tumors under stable condition, including new CNS metastasis without any syndrome, confirmed by imaging during screening period can be enrolled.
• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
• History of allogeneic organ transplant.
• Known history of infection with Human Immunodeficiency Virus (HIV) or other acquired or congenital immunodeficiency.
• Patients with serious psychiatric or medical condition that could interfere with medication adherence.
• Receiving systemic corticosteroid therapy (prednisone \>10 mg/day or Bioequivalent dose of hydrocortisone) within 2 week prior to the first dose of trial treatment or receiving any other form of systemic immunosuppressive medication, except the condition as described below: treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids, or short-term (≤7 days) use of glucocorticoids for prophylactic treatment.
• Active or history of autoimmune disease that requires systemic treatment within 2 years prior to enrollment (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). But the subjects with the following diseases are allowed to be enrolled: Type I diabetes with stable condition after using fixed dose insulin; Autoimmune hypothyroidism that only requires hormone replacement therapy.
• History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, interstitial pneumonia or evidence of active pneumonia detected during chest CT scan screening.
• Having experienced immune related adverse events of ≥ 3 grade during receiving any immunotherapy medication in the past.
• Adverse reactions from previous anti-tumor treatments have not yet recovered to ≤1 grade per CTCAE 5.0 (except alopecia and other adverse reactions that the investigator determines that there is no safety risk)
• Underwent major surgery within 4 weeks prior to the first dose of the study drug, or not fully recovered after surgery, or planned surgery within the expected participation time of the subject in the study or within 4 weeks after the last dose of the study drug.

Sponsors & Collaborators

• Jun Zhou: lead
• Fudan University: collaborator
• Hunan Cancer Hospital: collaborator
• Fujian Cancer Hospital: collaborator
• Shanghai Pulmonary Hospital, Shanghai, China: collaborator
• Shandong Cancer Hospital and Institute: collaborator
• Anyang Tumor Hospital: collaborator
• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine: collaborator

Study Sites (6)

Fujian Cancer Hospital

Fuzhou, Fujian, China

RECRUITING

Anyang tumor hospital

Anyang, Henan, China

RECRUITING

Cancer hospital of Shandong First Medical University

Jinan, Shandong, China

RECRUITING

Fudan University Shanghai cancer center

Shanghai, China

RECRUITING

Shanghai Pulmonary hospital

Shanghai, China

RECRUITING

Shanghai Xinhua hospital

Shanghai, China

RECRUITING

Central Study Contacts

Jun Zhou, Ph.D

CONTACT

(+86)18018182095; jun_zhou@immunourchin.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Study director, ImmnunoUrchin

Study Record Dates

• First Submitted: May 6, 2026
• First Posted: May 13, 2026
• Study Start: June 18, 2024
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): June 30, 2028
• Last Updated: May 13, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF

Locations

CN (6)